The MemoDerm Acellular Dermal Matrix is a terminally sterilized, single-application onlay graft used to promote healing of diabetic foot ulcers and other soft-tissue repairs.
Memometal MemoDerm line Marketing vice president Tommy Turpin said the new graft material is sterile, and therefore a significant improvement over the main competitor in the market. Several design features, combined with biological components, provide a dermal scaffold for blood vessel and tissue re-growth.
"In addition, MemoDerm Dermal Matrix is processed utilising a patent-pending method that minimizes the potential for immunogenic response, and preserves the natural histomorphology," Turpin said.
"In terms of safety, biomechanical strength and structural performance, MemoDerm Dermal Matrix is a higher-quality product, offering clinicians more flexibility and reliability."
MMI general manager Alan Taylor said MemoDerm Dermal Matrix further demonstrates Memometal Technologies’ commitment to improve the standard of care and expand the science in the Extremity Orthopedic Market.
